Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes.
Saved in:
| Title: | Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes. |
|---|---|
| Authors: | Kornelius E; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan., Lo SC; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan., Yang YS; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan., Wang YH; Chung Shan Medical University Hospital, Department of Medical Research, Taichung, Taiwan., Huang CN; Chung Shan Medical University, School of Medicine, Taichung, Taiwan.; Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung, Taiwan.; Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2025 Oct 20; Vol. 16, pp. 1686851. Date of Electronic Publication: 2025 Oct 20 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2025.1686851 |
